Discovery

Previous studies revealed that long-term ex vivo expansion and activation of autologous NK cells from Multiple myeloma patients provides significantly superior cytotoxic activity against autologous tumor cells when compared to short-term activated autologous NK cells (Alici, Sutlu et al. 2008). Furthermore, efficient NK cell-based treatment of Multiple myeloma development in an animal model has been reported (Alici, Konstantinidis et al. 2007). Having optimized the procedure for NK cell expansion in a closed-automated bioreactor using clinical grade GMP-compliant components, all the preclinical requirements were in place to get approval from the Swedish Medical Products Agency (EudraCT: 2010-022330-83) and the ethical committees (EPN: 2013/490-32) to initiate a first-in-human phase I/II clinical trial ACP-001 (Sutlu, Stellan et al. 2010, Sutlu and Alici 2011). The expanded cells are fully compliant with the EU ATMP Directive.

History

XNK Therapeutics’ technology platform is built on the world’s leading research on NK cells at Karolinska Institutet in Stockholm. Multiple myeloma is the leading indication for CellProtect.

2011

Cell therapy consortium initiated

vinnova
2012

XNK Therapeutics (then CellProtect Nordic Pharmaceuticals) is founded

2014

Patent granted for NK-cell expansion in the US and China

2017

Patent granted in the US for method to treat Multiple myeloma with expanded NK-cells

2018

ODD status by EMA

ema
2019

Patent for expansion of NK-cells granted in the EU and Japan

2020

Joins the NextGenNK consortium

nextgennk
2020

Johan Liwing is appointed as CEO

Johan Liwing
2020

Reports results from first-in-human phase I/II clinical trial and initiates planning for phase II clinical trials

2020

Research collaboration initiated with Cellect Biotechnology

cellect
2020

ODD status by the FDA

fda
2021

Research collaboration initiated with Sanofi

2021

SEK 64m private placement completed

2021

Dr. Johan Aschan and Michael Uhlin appointed as CMO and CSO, respectively

2021

First patient recruited to the phase II combination trial